Salivary Ultrasonography Research Articles

Salivary ultrasonography and histopathologic evaluation of secondary Sjögren’s syndrome in rheumatoid arthritis patients

Novel modalities, such as salivary ultrasonography (SGUS) and shear wave elastography (SWE), have previously been introduced to evaluate Sjögren’s syndrome (SS). However, in secondary SS (sSS), the diagnostic performance of SGUS and its relationship with clinicopathological characteristics have not yet been clearly defined. In this study, we aimed to investigate sSS in RA patients using SGUS and SWE and sought to determine its pathological correlations. Thirty-one RA patients who presented with sicca symptoms were included to be evaluated on SS, and were compared with 18 primary SS (pSS) patients. All subjects were assessed through SGUS, SWE, and conventional diagnostic approaches for SS, including minor salivary gland biopsy (MSGB). In SGUS evaluation, two separate scoring systems, suggested by Hocevar and OMERACT, were used. Among 31 RA patients with sicca symptoms, 19 (61.2%) were diagnosed as sSS. Similar to pSS, SGUS showed good diagnostic performance (sensitivity 68.4% and 78.9%, and specificity 91.7% and 75.0% for Hocever and OMERACT, respectively) in differentiating sSS from RA patients with simple sicca symptoms. The sSS and pSS patients exhibited significantly higher lymphoid infiltration areas in MSGB than RA patients without SS. Focus score and lymphoid infiltration areas correlated well with sonographic severity. Severity of fibrosis in MSGB showed better positive correlation with SWE than with SGUS. Similar to pSS, SGUS shows good diagnostic performance for sSS in RA patients. SWE reflects histopathologic chronicity of MSGB well in both pSS and sSS.

Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.

ObjectivesTo assess the association between salivary ultrasonography (sUS) findings and disease activity and damage in patients with primary Sjogren’s syndrome (pSS). We investigated the potential prognostic role of sUS as a tool in the assessment of disease activity.MethodsIn 303 pSS patients, disease activity was assessed by the European League Against Rheumatism (EULAR) Sjogren’s Syndrome Disease Activity Index (ESSDAI), the EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI), the Sjogren’s Syndrome Disease Activity Index (SSDAI) and the Sjogren’s Syndrome Disease Damage Index (SSDDI). The sUS parenchymal inhomogeneity (de Vita scoring system) was assessed in 303 pSS patients and 111 heathy controls. A receiver operating characteristic (ROC) curve was used to determine the cut-off value of the pathological sUS score. Logistic regression analysis was performed to assess risk factors for moderate and high disease activity.ResultsA pathological sUS score ≥ 2 was recorded in 271 (89.7%) patients and 8 (8.6%) healthy controls. Patients with moderate and high ESSDAI and SSDAI scores had significantly higher US activity in comparison to that of pSS patients with low disease activity (p = 0.006; p = 0.01, respectively). Additionally, pSS patients with moderate and high SSDDI scores had higher US activity (p = 0.031). Pathological sUS correlated with the glandular domain within the ESSDAI and SSDDI (p<0.001). The patients with a severe US score (5–6) had a 3.5 times greater chance of having moderate or high disease activity. The specificity of the severe de Vita sUS score for ESSDAI and SSDAI was 85.1% and 85.2%, respectively. In contrast, the sensitivity of a severe de Vita sUS score for ESSDAI was low, at 29.2%, while the sensitivity for the SSDAI was higher, 42.3%. In the analysis of disease activity, a de Vita score ≥ 5 could be used as a risk factor for moderate and high ESSDAI (p = 0.042) and SSDAI (p = 0.006).ConclusionsPathological salivary gland ultrasonography is associated with high disease activity and damage in pSS. Consequently, sUS abnormalities might be surrogate items for glandular domains in the assessment of disease activity and damage. Thus, ultrasonography of the salivary gland combined with clinical and serological markers might be part of the next prognostic and therapeutic algorithm in the near future.

Salivary gland ultrasonography as a primary imaging tool for predicting efficacy of xerostomia treatment in patients with Sjögren's syndrome.

To evaluate ultrasonography (US) grading of salivary gland disease as a predictor of treatment efficacy for impaired salivary function in xerostomia patients with or without Sjögren's syndrome (SS). We retrospectively analysed the prognostic importance of salivary US grading in 317 patients (168 with SS and 149 without SS). US images of the parotid and submandibular glands in each patient were individually categorized into grades 0-4 based on the extent of damage to the gland; and the sum total grade of the two gland types on either side was assigned a US score of 0-8 for each patient. The relative importance of US score and demographic and clinical variables was assessed using stepwise multiple regression analysis after various durations of xerostomia treatment. Multiple regression analysis indicated that the baseline US score before treatment was the most important factor [standardized regression coefficient (β) = -0.523, t-statistic (t) = -7.967, P < 0.001] in predicting negative outcomes in SS patients. Treatment duration (β = 0.277, t = 4.225, P < 0.001) was also a significant but less important positive variable. On the other hand, US grading did not effectively predict treatment outcomes in non-SS patients, with treatment duration (β = 0.199, t = 2.486, P = 0.014) and baseline salivary flow rate before treatment (β = -0.172, t = -2.159, P = 0.032) being significant but weak predictors of positive and negative outcome, respectively. Salivary gland US grading may help to predict outcomes of treatment for impaired salivary function in patients with SS.

Salivary Gland Ultrasonography and Its Spplications in Patients with Sjögren's Syndrome and Sicca Symptoms: A Preliminary Report

Objective: To assess the utility of salivary gland ultrasonography for Sjogren's syndrome and patients with sicca symptoms, including the correlations between clinical parameters and patients' symptoms. Methods: Patients that fulfilled the classification criteria proposed by American College of Rheumatology for primary Sjogren's syndrome and secondary Sjogren's syndrome, and patients with sicca symptoms were enrolled. A total of 25 patients were collected. Their clinical and serological data were obtained from medical records and laboratory databases. Salivary ultrasonography was performed for parotid glands and submandibular glands, and each gland was scored 0-4, with a total maximum score of 16. The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) was arranged for evaluation of patient symptoms. Results: The median ESSPRI scores for primary Sjogren's syndrome and secondary Sjogren's syndrome, and for patients with sicca symptoms were 13.00 (IQR: 5.00-16.00), 11.00 (IQR: 7.00-15.00), and 10.50 (IQR: 5.50-19.75), respectively. The salivary gland ultrasonography score correlated with the serum anti- La/SSB (β-coefficient 0.022, p 0.026), total ESSPRI score (β-coefficient 0.337, p 0.02) and dryness score (β-coefficient 0.717, p 0.035), but not with the serum anti-Ro/SSA level, pain score, and fatigue score. Conclusion: Salivary ultrasonography provides a easy access for evaluation of the severity of salivary gland involvement in patients with Sjogren's syndrome and sicca symptoms, and correlates with the patients' clinical symptoms score and serum anti-La/SSB level; therefore, they may be parameters that can be used in evaluating patients with Sjogren's syndrome.